Cytek Biosciences Inc (CTKB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -66,539 | -6,020 | -12,148 | 2,484 | 3,027 |
| Depreciation Amortization | 11,975 | 10,490 | 9,230 | 5,659 | 1,242 |
| Income taxes - deferred | 33,557 | -2,886 | 0 | N/A | N/A |
| Accounts receivable | 368 | -5,428 | -7,332 | -19,744 | -12,367 |
| Accounts payable and accrued liabilities | 448 | 2,582 | -1,784 | 1,862 | -256 |
| Other Working Capital | -4,794 | 7,713 | -10,509 | -39,928 | -8,646 |
| Other Operating Activity | 20,299 | 18,928 | 27,824 | 37,436 | 21,630 |
| Operating Cash Flow | $-4,686 | $25,379 | $5,281 | $-12,231 | $4,630 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 14,056 | -79,062 | -43,935 | -44,454 | 0 |
| PPE Investments | -3,832 | -3,237 | -4,648 | -9,748 | -4,364 |
| Net Acquisitions | N/A | -471 | -44,896 | N/A | -17,000 |
| Purchase Of Investment | N/A | N/A | -236 | -1,587 | 371 |
| Purchase Sale Intangibles | -106 | -204 | -179 | -120 | N/A |
| Other Investing Activity | -107 | -204 | -179 | -120 | 0 |
| Investing Cash Flow | $10,117 | $-82,974 | $-93,894 | $-55,909 | $-20,993 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 5,582 | 4,181 | 0 | 0 | N/A |
| Debt Issued | N/A | N/A | N/A | 2,983 | N/A |
| Debt Repayment | -4,745 | -557 | -565 | -50 | -2,772 |
| Common Stock Issued | 325 | 1,015 | 1,468 | 1,204 | 216,331 |
| Common Stock Repurchased | -13,925 | -19,907 | -42,296 | 1,585 | N/A |
| Other Financing Activity | -669 | -554 | -419 | -209 | 0 |
| Financing Cash Flow | $-13,432 | $-15,822 | $-41,812 | $5,513 | $213,559 |
| Exchange Rate Effect | 109 | 4,532 | -1,445 | -2,491 | 1,303 |
| Beginning Cash Position | 98,745 | 167,630 | 299,500 | 364,618 | 166,119 |
| End Cash Position | 90,853 | 98,745 | 167,630 | 299,500 | 364,618 |
| Net Cash Flow | $-7,892 | $-68,885 | $-131,870 | $-65,118 | $198,499 |
| Free Cash Flow | |||||
| Operating Cash Flow | -4,686 | 25,379 | 5,281 | -12,231 | 4,630 |
| Capital Expenditure | -4,084 | -3,525 | -4,648 | -9,748 | -4,364 |
| Free Cash Flow | -8,770 | 21,854 | 633 | -21,979 | 266 |